Indications
mResvia is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by Respiratory Syncytial Virus (RSV) in adults 18 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Composition
- Active substance
- Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation
- International name (INN)
- respiratory syncytial virus mRNA vaccine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- mResvia
- ATC code
- J07BX05
- Therapeutic area
- Respiratory Syncytial Virus Infections